Advertisement


Alberto Bossi, MD, on Prostate Cancer: PEACE-1 Trial Findings on Radiotherapy Plus Systemic Treatment

2023 ASCO Annual Meeting

Advertisement

Alberto Bossi, MD, of Institut Gustave Roussy, discusses phase III findings showing that combining prostate radiotherapy with systemic treatment did not improve overall survival in men with de novo metastatic castration-sensitive prostate cancer and low metastatic burden. However, best outcomes (radiographic progression–free-survival and overall survival) were observed in men receiving the standard of care plus abiraterone acetate plus prednisone with radiotherapy (Abstract LBA5000).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Alberto Bossi, MD: PEACE-1 is a randomized Phase III trial with four arms that has been designed some 11 years ago in order to study a very precise population of patients, which is patients presenting de novo of diagnosis with metastatic prostate cancer. There has been a huge landscape movement in the last years concerning this subgroup of patients and PEACE-1 has specifically been designed to answer two questions. First of all, the benefit of abiraterone on top of standard of care, and second, to detect if any benefit of local radiotherapy, prostate radiotherapy would be important for those patients, so two questions, four arms. Standard of care has been updated during the inclusion period of the study because we had some new evidence coming from the literature, and so the use of chemotherapy, docetaxel, has been at first introduced and compulsory at the end of the trial, four arms, so that have been compared and two main endpoints, radiographic progression-free survival and overall survival. Then a list of secondary endpoints, which we also discuss. What we discovered, in terms of overall survival, no difference between the use of local radiotherapy in those patients, both in the low volume population so patients presenting with low volume metastatic disease as in the high volume population, patients presenting with high burden of metastatic disease, no impact of radiotherapy. But using radiotherapy translates in a better radiographic progression-free survival, which was the second co-primary endpoint. We then had a list of secondary endpoints and we made studies on three of them. First, castration resistant state, and we discovered that giving radiotherapy in the prostate on those patients delays the onset of the castration resistant state, and this in a significant way. And second, that also in terms of secondary events locally in the prostate, radiotherapy may delay the need of a secondary treatment for those patients. Altogether, I think that in terms of quality of life for our patients these are very important outcomes. What's next? Well, first we have to dig into those data with much more details. There are still some open questions there. You are probably aware of the result of the STAMPEDE trial, the English trial which has exactly done the same as our trial and that has shown an improvement in overall survival, why our data do not show the same, so this is something we will try to dig later on. And secondary, there are a list of other endpoints which we also will try to study more details. The secondary endpoints are also important, especially in terms of quality of life for our patients. What is reassuring, and this is the end, what is reassuring is that no added toxicity was due to radiotherapy in the prostate and I think that this is very good and reassuring information for our patients and their family.

Related Videos

Lymphoma

Muhit Özcan, MD, on DLBCL: Early Results on Zilovertamab Vedotin

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses phase II findings from the waveLINE-004 study. It showed that the antibody-drug conjugate zilovertamab vedotin had clinically meaningful antitumor activity in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who experienced disease progression after, or have been ineligible for, autologous stem cell transplantation and/or chimeric antigen receptor T-cell therapy (Abstract 7531).

Skin Cancer
Immunotherapy

Jason J. Luke, MD, on Melanoma Adjuvant Therapy: Final Analysis of KEYNOTE-716

Jason J. Luke, MD, of the University of Pittsburgh Medical Center Hillman Cancer Center, discusses adjuvant pembrolizumab, which, in previous results, improved distant metastasis– and recurrence-free survival in patients with resected stage IIB or IIC melanoma vs placebo. After a median follow-up of 39.4 months, adjuvant pembrolizumab continued to show a benefit over placebo, with no new safety signals (Abstract LBA9505).

Kidney Cancer

Rana R. McKay, MD, and Toni K. Choueiri, MD, on RCC: New Findings on Efficacy and Safety of Atezolizumab Plus Cabozantinib

Rana R. McKay, MD, of the University of California, San Diego, and Toni K. Choueiri, MD, of Dana-Farber Cancer Institute and Harvard Medical School, discuss results from the phase III CONTACT-03 study, showing that, for patients with metastatic renal cell carcinoma (RCC), adding the PD-L1 inhibitor atezolizumab to cabozantinib did not improve clinical outcomes compared with treatment with cabozantinib alone. In addition, higher toxicities were observed in the combination arm (Abstract LBA4500).

Lymphoma

Nirav N. Shah, MD, on DLBCL: New Data on Split-Dose R-CHOP for Older Patients

Nirav N. Shah, MD, of the Medical College of Wisconsin, discusses phase II results showing that split-dose R-CHOP offers older patients with diffuse large B-cell lymphoma (DLBCL) an equivalent dose intensity as R-CHOP-21 through a fractionated dosing schedule, improving tolerability. At the end of treatment for these older patients, a complete response rate of 71% was comparable to outcomes with R-CHOP in younger patients with the disease (Abstract 7554).

Skin Cancer
Immunotherapy

Omid Hamid, MD, on Advanced Melanoma: Durable Response With Fianlimab Plus Cemiplimab

Omid Hamid, MD, of The Angeles Clinic & Research Institute, discusses study findings on fianlimab plus cemiplimab-rwlc, which showed clinical activity in patients with advanced melanoma, comparing favorably with other approved combinations of immune checkpoint inhibitors in the same clinical setting. This is the first indication that dual LAG-3 blockade may produce a high level of activity with significant overall response rate after adjuvant anti–PD-1 treatment. A phase III trial of this regimen in treatment-naive patients with advanced melanoma is ongoing (Abstract 9501).

Advertisement

Advertisement




Advertisement